PIC Therapeutics, a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, announced the closing of a $35 million Series A financing led by OrbiMed.

Other new investors participating in this financing include Lumira Ventures and Harrington Discovery Institute. The company's existing investors including Advent Life Sciences and Belinda Termeer also participated and provided initial seed financing instrumental to meeting key milestones.